Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).
Cash totaled $5.6M as of Sep 30, 2024, down from $23.4M at Dec 31, 2023.
108 patients have completed 1 year of treatment in brilaroxazine OLE trial; topline data expected December 2024.
NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026; RECOVER-2 start expected Q1 2025 pending financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.